Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondylarthropathies
- 2 December 2005
- journal article
- clinical trial
- Published by Wiley in Arthritis & Rheumatism
- Vol. 52 (12) , 3898-3909
- https://doi.org/10.1002/art.21426
Abstract
Objective: Because different tumor necrosis factor α (TNFα) blockers may have distinct immunomodulatory effects on specific disease manifestations, the present study was carried out to investigate the immunomodulating effects of etanercept on peripheral synovitis in the spondylarthropathies (SpA).Methods: Peripheral joint disease was assessed clinically, histologically, and radiologically in a prospective 2‐year study of 20 patients with SpA treated with etanercept. Synovial tissue biopsy samples obtained at weeks 0, 12, and 52 were analyzed by histology and immunohistochemistry for the extent of inflammation, changes to tissue architecture, and matrix degradation. Serum levels of myeloid‐related protein 8 (MRP‐8)/MRP‐14, matrix metalloproteinase 3 (MMP‐3), and cartilage oligomeric matrix protein (COMP) were determined by enzyme‐linked immunosorbent assay.Results: Etanercept induced a rapid and sustained clinical improvement of peripheral joint disease. Histologic synovitis was down‐regulated, with a profound reduction in global cellular infiltration and T lymphocytes, but not B lymphocytes. The most prominent change in markers of inflammation was a reduction in the different macrophage subsets (CD68, CD163, MRP‐8, and MRP‐14), but this was not paralleled by a decrease in serum MRP‐8/MRP‐14. Structural changes included normalization of lining layer hyperplasia and a moderate reduction in vascularity. However, no effect on the microarchitecture of lymphoid aggregates was observed. In terms of an effect on matrix degradation, the synovial expression of MMP‐3 and MMP‐9 was down‐modulated in correlation with a rapid and profound decrease in serum MMP‐3. At week 52, serum COMP levels were also reduced. No significant radiologic disease progression was observed in these patients over a 2‐year period.Conclusion: Use of etanercept effectively down‐modulated the immunopathologic processes of SpA synovitis, both in the short term and in the long term.Keywords
This publication has 53 references indexed in Scilit:
- Differential expression and response to anti‐TNFα treatment of infiltrating versus resident tissue macrophage subsets in autoimmune arthritisThe Journal of Pathology, 2005
- Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitisAnnals of the Rheumatic Diseases, 2004
- Diagnostic classification of spondylarthropathy and rheumatoid arthritis by synovial histopathology: A prospective study in 154 consecutive patientsArthritis & Rheumatism, 2004
- Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down‐regulation by tumor necrosis factor α blockade in spondylarthropathyArthritis & Rheumatism, 2004
- Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progressionArthritis & Rheumatism, 2004
- The effect of etanercept and infliximab on the production of tumour necrosis factor α, interferon-γ and GM-CSF in in vivo activated intestinal T lymphocyte culturesCytokine, 2003
- Successful use of infliximab in a patient with treatment resistant spondyloarthropathy related uveitisAnnals of the Rheumatic Diseases, 2002
- Macrophages expressing the scavenger receptor CD163: a link between immune alterations of the gut and synovial inflammation in spondyloarthropathyThe Journal of Pathology, 2002
- Complementation of Lymphotoxin α Knockout Mice with Tumor Necrosis Factor–expressing Transgenes Rectifies Defective Splenic Structure and FunctionThe Journal of Experimental Medicine, 1998
- Evaluation of Diagnostic Criteria for Ankylosing SpondylitisArthritis & Rheumatism, 1984